In 2004, Dr. Scott Rocklage, became Managing Partner of 5AM Ventures. With over 20 years of healthcare management experience, Dr. Rocklage’s role as Managing Partner was more than welcomed due to his extraordinary strategic leadership skills. His direct knowledge of FDA drug applications led to 5AM Ventures successfully achieving the approval of three U.S. drugs, namely; Omniscan, Teslascan and Cubicin. Ultimately, this approval resulted in six new clinical trials.
Dr. Scott Rocklage has a Bachelor’s of Science degree in Chemistry, received from the University of California, in Berkley. Additionally, he received his PH.D in chemistry by attending the Massachusetts Institute of Technology. Dr. Rocklage serves as a board Chairmen of Achaogen, Relypsa and Semprus, in addition to being a board member of several others.
5AM Ventures is an advanced life science technology company. They’re dedicated in providing diversified bio-pharmaceutical, medical technology, and research sectors. The company’s strategy is to implement and evaluate innovative technologies within those sectors, as well as corporate spin offs, and essential products that have short development cycles, in order to invest throughout various therapeutic platforms. The forecast outcome, for each investment, is to generate favorable returns within a minimum of three years and a maximum of five years combined.
Dr. Rocklage conducted a lengthy laboratory project, working alongside 2005 Nobel Prize winner in Chemistry, Richard R. Schrock, where he gained a thorough understanding of organic chemistry and metathesis reaction, a core-foundation of Mr. Schrock’s influential research. Currently, Dr. Rocklage has over 100 peer-reviewed national publications, and he is the inventor, or co-inventor, of more than 30 patents within the United States and learn more about Scott.
Based in Boston, Massachusetts, Dr. Rocklage contributes to studying new areas of life science, working with entrepreneurs, scientists, physicians, or business executives. His ideas are regularly championed to assist business leaders with implementing strategies, for shaping potential medicines and treating uncharted medical needs and contact him.
Dr. Rocklage’s awareness of being able to target and direct, specific mutations, or genotypes, to treat cancer in as many unique ways as possible, is well sought-after. He has contributed greatly to extending and saving lives, as well as developing medical improvements, for the future and read full article.